DM-199 is a novel human recombinant protein and second-generation version of DM-99.

DM-199 was shown to have a dramatic effect on C-peptide levels, increasing them 12-fold in a preclinical study.  This is significant as C-peptide levels are the primary end-point in most Type 1 diabetes clinical trials. In addition, other studies at multiple research sites have shown DM-199 to be strong clinical candidate for the treatment of Type 1 diabetes. 

The Company has also demonstrated that DM-199 has similar activity to DM-99 in increasing whole body glucose uptake in animals using the hyperinsulemic euglycemic clamp model.  This, among other study results, positions DM-199 as an excellent candidate for the treatment of Type 2 diabetes.  

By developing the improved recombinant human version, DiaMedica will also take advantage of the clinical efficacy and safety of the Company’s first-generation DM-99.

DM-199 is a recombinant human protein that protects specific cells via the expansion of a population of antigen-specific immunosuppressive cells (Tregs), proliferates specific cells through the activation of certain growth factors and improves glucose control.